2023
Challenger, E., Penchala, S. D., Hale, C., Fitzgerald, R., Walker, L., Reynolds, H., . . . Else, L. (2023). Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 233. doi:10.1016/j.jpba.2023.115436DOI: 10.1016/j.jpba.2023.115436
A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin (Journal article)
Rametse, C. L., Webb, E., Herrera, C., Alinde, B., Besethi, A., Motaung, B., . . . CHAPS, C. (2023). A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin. AIDS, 37(11), 1651-1659. doi:10.1097/QAD.0000000000003619DOI: 10.1097/QAD.0000000000003619
Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS (Journal article)
Thompson, B., Dilly-Penchala, S., Amara, A., Reynolds, H., Khoo, S., & Else, L. (2023). Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS. BIOANALYSIS, 15(13), 739-756. doi:10.4155/bio-2023-0057DOI: 10.4155/bio-2023-0057
2019
Murtagh, R., Else, L. J., Kuan, K. B. K., Khoo, S. H., Jackson, V., Patel, A., . . . Lambert, J. S. (2019). Therapeutic drug monitoring of darunavir/ritonavir in pregnancy. ANTIVIRAL THERAPY, 24(3), 229-233. doi:10.3851/IMP3291DOI: 10.3851/IMP3291
2016
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55(7), 861-873. doi:10.1007/s40262-015-0360-5DOI: 10.1007/s40262-015-0360-5
2015
Dickinson, L., Yapa, H. M., Jackson, A., Moyle, G., Else, L., Amara, A., . . . Boffito, M. (2015). Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(10), 6080-6086. doi:10.1128/AAC.01441-15DOI: 10.1128/AAC.01441-15
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.. Clinical pharmacology and therapeutics, 98(4), 406-416. doi:10.1002/cpt.156DOI: 10.1002/cpt.156
Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study (Journal article)
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317DOI: 10.1093/cid/civ317
Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies (Journal article)
Waitt, C. J., Garner, P., Bonnett, L. J., Khoo, S. H., & Else, L. J. (2015). Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(7), 1928-1941. doi:10.1093/jac/dkv080DOI: 10.1093/jac/dkv080
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study (Journal article)
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.
A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers (Journal article)
Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Cooke, G., . . . Winston, A. (2015). A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(6), 1812-1815. doi:10.1093/jac/dkv035DOI: 10.1093/jac/dkv035
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. (Journal article)
Di Yacovo, M. S., Moltó, J., Ferrer, E., Curran, A., Else, L., Gisslén, M., . . . Podzamczer, D. (2015). Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.. The Journal of antimicrobial chemotherapy, 70(5), 1513-1516. doi:10.1093/jac/dku558DOI: 10.1093/jac/dku558
Else, L., Back, D., Khoo, S. H., & Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.. The Journal of Antimicrobial Chemotherapy, 70(5), 1482-1486. doi:10.1093/jac/dku575DOI: 10.1093/jac/dku575
Amara, A. B., Else, L. J., Tjia, J., Olagunju, A., Puls, R. L., Khoo, S., & Back, D. J. (2015). A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography-Mass Spectrometry. THERAPEUTIC DRUG MONITORING, 37(2), 220-228. doi:10.1097/FTD.0000000000000127DOI: 10.1097/FTD.0000000000000127
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically-defined subgroups of mother-infant pairs: an observational study.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
Winston, A., Amin, J., Clarke, A., Else, L., Amara, A., Owen, A., . . . Puls, R. (2015). Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial. CLINICAL INFECTIOUS DISEASES, 60(7), 1026-1032. doi:10.1093/cid/ciu976DOI: 10.1093/cid/ciu976
Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics (Journal article)
Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 97(3), 298-306. doi:10.1002/cpt.43DOI: 10.1002/cpt.43
Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. (Journal article)
Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.. Clinical pharmacology and therapeutics, 97(3), 298-306.
A PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF BOCEPREVIR AND SILDENAFIL WHEN DOSED SEPARATELY AND TOGETHER, IN HEALTHY MALE VOLUNTEERS (Journal article)
Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Graham, C., . . . Winston, A. (2015). A PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF BOCEPREVIR AND SILDENAFIL WHEN DOSED SEPARATELY AND TOGETHER, IN HEALTHY MALE VOLUNTEERS. SEXUALLY TRANSMITTED INFECTIONS, 91, A78. doi:10.1136/sextrans-2015-052126.231DOI: 10.1136/sextrans-2015-052126.231
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420DOI: 10.1093/jac/dku420
Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. (Journal article)
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.. The Journal of antimicrobial chemotherapy, 70(2), 555-561.
Reynolds, H. E., Chrdle, A., Egan, D., Chaponda, M., Else, L., Chiong, J., . . . Khoo, S. H. (2015). Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.. The Journal of antimicrobial chemotherapy, 70(2), 550-554.
The pharmacokinetic profile of raltegravircontaining antiretroviral therapy in HIV-infected individuals over 60 years of age (Journal article)
Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravircontaining antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV CLINICAL TRIALS, 16(1), 39-42. doi:10.1179/1528433614Z.0000000006DOI: 10.1179/1528433614Z.0000000006
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. (Journal article)
Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.. HIV clinical trials, 16(1), 39-42.
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults (Journal article)
Lamorde, M., Walimbwa, S., Byakika-Kibwika, P., Katwere, M., Mukisa, L., Sempa, J. B., . . . Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. J Antimicrob Chemother, 70(5), 1482-1486.
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy. (Journal article)
Waters, L., Jackson, A., Else, L., Rockwood, N., Newell, S., Back, D., . . . Boffito, M. (2015). Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.. Antiviral therapy, 20(2), 157-163. doi:10.3851/imp2817DOI: 10.3851/imp2817
2014
Darunavir pharmacokinetics throughout pregnancy and postpartum (Journal article)
Lambert, J., Jackson, V., Else, L., Lawless, M., McDonald, G., Le Blanc, D., . . . Khoo, S. (2014). Darunavir pharmacokinetics throughout pregnancy and postpartum. J Int AIDS Soc, 17(4 Supp), 19485.
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant (Journal article)
Scarsi, K., Lamorde, M., Darin, K., Dilly Penchala, S., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int AIDS Soc, 17(4 Supp), 19484.
Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy (Journal article)
Else, L., Jackson, V., Brennan, M., Back, D. J., Khoo, S. H., Coulter-Smith, S., & Lambert, J. S. (2014). Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. HIV Medicine, 15(10), 604-610. doi:10.1111/hiv.12164DOI: 10.1111/hiv.12164
No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals (Journal article)
Singh, G. J., Jackson, A., D'Avolio, A., Else, L., De Nicolo, A., Bonora, S., . . . Boffito, M. (2014). No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals. AIDS, 28(13), 1993-1995. doi:10.1097/QAD.0000000000000356DOI: 10.1097/QAD.0000000000000356
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. (Journal article)
Jackson, A., D'Avolio, A., Moyle, G., Bonora, S., Di Perri, G., Else, L., . . . Boffito, M. (2014). Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.. The Journal of antimicrobial chemotherapy, 69(7), 1911-1915. doi:10.1093/jac/dku060DOI: 10.1093/jac/dku060
A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis (Journal article)
Jackson, A. G. A., Else, L. J., Mesquita, P. M. M., Egan, D., Back, D. J., Karolia, Z., . . . Boffito, M. (2014). A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(3), 314-323. doi:10.1038/clpt.2014.118DOI: 10.1038/clpt.2014.118
DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI. (Journal article)
Di Yacovo, S., Molto, J., Ferrer, E., Curran, A., Else, L., Clotet, B., . . . Podzamczer, D. (2014). DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI.. Journal of the International AIDS Society, 17(4 Supp), 19821.
Darunavir pharmacokinetics throughout pregnancy and postpartum (Poster)
Lambert, J., Jackson, V., Else, L., Lawless, M., McDonald, G., Le Blanc, D., . . . Khoo, S. (2014). Darunavir pharmacokinetics throughout pregnancy and postpartum. Poster session presented at the meeting of Unknown Conference. Retrieved from https://www.webofscience.com/DOI: 10.7448/IAS.17.4.19485
Scarsi, K., Lamorde, M., Darin, K., Penchala, S. D., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant.. doi:10.7448/ias.17.4.19484DOI: 10.7448/ias.17.4.19484
2013
The importance of drug-drug interactions in the DAA era. (Journal article)
Back, D., & Else, L. (2013). The importance of drug-drug interactions in the DAA era.. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 45 Suppl 5, S343-S348. doi:10.1016/j.dld.2013.07.008DOI: 10.1016/j.dld.2013.07.008
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics. (Journal article)
Moyle, G., Else, L., Jackson, A., Back, D., Yapa, M. H., Seymour, N., . . . Boffito, M. (2013). Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.. Antimicrobial agents and chemotherapy, 57(8), 3640-3644. doi:10.1128/aac.00357-13DOI: 10.1128/aac.00357-13
Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer (Journal article)
Penchala, S. D., Tjia, J., El Sherif, O., Back, D. J., Khoo, S. H., & Else, L. J. (2013). Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 932, 100-110. doi:10.1016/j.jchromb.2013.06.013DOI: 10.1016/j.jchromb.2013.06.013
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. (Journal article)
Mora-Peris, B., Croucher, A., Else, L. J., Vera, J. H., Khoo, S., Scullard, G., . . . Winston, A. (2013). Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.. The Journal of antimicrobial chemotherapy, 68(6), 1348-1353. doi:10.1093/jac/dkt006DOI: 10.1093/jac/dkt006
Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma. (Journal article)
Dufty, N. E., Gilleran, G., Hawkins, D., Else, L. J., & Taylor, S. (2013). Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma.. The Journal of antimicrobial chemotherapy, 68(4), 972-974. doi:10.1093/jac/dks486DOI: 10.1093/jac/dks486
2012
Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP) (Journal article)
Watson, V., Else, L., Tjia, J., Khoo, S., & Back, D. (2012). Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP). Journal of the International AIDS Society, 15(S4), 1. doi:10.7448/ias.15.6.18336DOI: 10.7448/ias.15.6.18336
Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF) (Poster)
Watson, V., Tjia, J., Szwandt, S., Else, L., Khoo, S., & Back, D. (2012). Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF). Poster session presented at the meeting of 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain.
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study (Journal article)
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrobial Agents and Chemotherapy, 56(3), 1427-1433.
Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations (Journal article)
Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 816-824. doi:10.1128/AAC.05186-11DOI: 10.1128/AAC.05186-11
Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. (Journal article)
Else, L., Douglas, M., Dickinson, L., Back, D., Khoo, S., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.
Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. (Journal article)
Else, L., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study (Journal article)
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother, 56(3), 1427-1433.
Pharmacokinetics of plasma lamivudine (3TC) and its active intracellular anabolite 3TC-triphosphate (3TC-TP) over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily (od) to HIV-negative healthy volunteers. The ENCORE 2 Study. (Journal article)
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of plasma lamivudine (3TC) and its active intracellular anabolite 3TC-triphosphate (3TC-TP) over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily (od) to HIV-negative healthy volunteers. The ENCORE 2 Study.. Antimicrob Agents Chemother.
co-author (Conference Paper)
Jackson, A., Else, L., Tjia, J., Seymour, N., Stafford, M., Back, D., . . . Boffito, M. (2012). co-author. In 19th Conference on Retroviruses and Opportunistic Infections (pp. Paper #35). Seattle: CROI.
2011
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid) (Journal article)
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). ANTIVIRAL THERAPY, 16(8), 1139-1147. doi:10.3851/IMP1918DOI: 10.3851/IMP1918
Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract (Journal article)
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract. Antiviral Therapy, 16(8), 1149-1167. doi:10.3851/imp1919DOI: 10.3851/imp1919
Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies (Journal article)
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6), 2775-2782. doi:10.1128/AAC.00887-10DOI: 10.1128/AAC.00887-10
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies. (Journal article)
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.. Antimicrobial agents and chemotherapy, 55(6), 2775-2782.
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy (Journal article)
Else, L. J., Lyons, F., O'Shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. AIDS, 25(5), 722-725. doi:10.1097/QAD.0b013e3283445700DOI: 10.1097/QAD.0b013e3283445700
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. (Journal article)
Else, L., Lyons, F., O'shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.. AIDS, 25(5), 722-725.
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy (Journal article)
Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.xDOI: 10.1111/j.1468-1293.2010.00865.x
Pharmacokinetics of plasma lamivudine (3TC) and its active intracellular anabolite 3TC-triphosphate (3TC-TP) over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily (od) to HIV-negative healthy volunteers. The ENCORE 2 Study. (Conference Paper)
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2011). Pharmacokinetics of plasma lamivudine (3TC) and its active intracellular anabolite 3TC-triphosphate (3TC-TP) over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily (od) to HIV-negative healthy volunteers. The ENCORE 2 Study.. In 12th International Workshop on Clinical Pharmacology of HIV Therapy (pp. oral communication). Miami: Virology Education.
Saliva Nevirapine (NVP) Concentrations as an Alternative Biofluid for NVP Pharmacokinetics (PK) in HIV-infected Children. (Conference Paper)
Else, L., Sabo, J., Yong, C., Macgregor, T. R., Eaton, S., Rinck, G., . . . Back, D. J. (2011). Saliva Nevirapine (NVP) Concentrations as an Alternative Biofluid for NVP Pharmacokinetics (PK) in HIV-infected Children.. In 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (pp. A1-A1164). Chicago: American Society for Microbiology.
Sequential population modelling of lopinavir and ritonavir in healthy volunteers and assessment of different doing strategies (Journal article)
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population modelling of lopinavir and ritonavir in healthy volunteers and assessment of different doing strategies. Antimicrob Agents Chemother, 55(6), 2775-2782.
2010
Darunavir concentrations exceed the protein-corrected EC(50) for wild-type HIV in the semen of HIV-1-infected men (Journal article)
Taylor, S., Jayasuriya, A. N., Berry, A., Gilleran, G., Dufty, N. E., Else, L., . . . Smit, E. J. (2010). Darunavir concentrations exceed the protein-corrected EC(50) for wild-type HIV in the semen of HIV-1-infected men. AIDS, 24(16), 2574-2577. doi:10.1097/QAD.0b013e32833ead18DOI: 10.1097/QAD.0b013e32833ead18
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds (Journal article)
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 878(19), 1455-1465. doi:10.1016/j.jchromb.2010.03.036DOI: 10.1016/j.jchromb.2010.03.036
Evaluating the affect of gender on darunavir and ritonavir (DRV/r) exposure in HIV infected subjects (a post-hoc analysis of the GRACE PK sub-study). (Conference Paper)
Else, L., Liptrott, N., Moss, D., Dutton, J., Fraser, W., Kakuda, T., . . . Back, D. (2010). Evaluating the affect of gender on darunavir and ritonavir (DRV/r) exposure in HIV infected subjects (a post-hoc analysis of the GRACE PK sub-study).. In 11th International Workshop on Clinical Pharmacology of HIV Therapy. (pp. P19). Sorrento: Virology Education.
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. (Journal article)
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. J Antimicrob Chemother..
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. (Journal article)
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. J Antimicrob Chemother..
Raltegravir (RAL) in combination with etravirine (ETV) - is there a case for therapeutic drug monitoring (TDM) in clinical practice? (Conference Paper)
Leake Date, H., Else, L., Dosekun, O., Back, D., Nathan, B., Kulasegaram, R., & Aboud, M. (2010). Raltegravir (RAL) in combination with etravirine (ETV) - is there a case for therapeutic drug monitoring (TDM) in clinical practice?. In Second Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH). (pp. P6). Manchester: BHIVA.
Therapeutic drug monitoring (TDM) of lopinavir/ritonavir (LPV/r) in pregnancy. (Conference Paper)
Else, L., Lambert, J. S., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. (2010). Therapeutic drug monitoring (TDM) of lopinavir/ritonavir (LPV/r) in pregnancy.. In Second Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH). (pp. P12). Manchester: HIV Med.
Therapeutic drug monitoring of lopinavir in pregnancy. (Journal article)
Lambert, J. S., Else, L., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2010). Therapeutic drug monitoring of lopinavir in pregnancy.. HIV Med. doi:10.1111/j.1468-1293.2010.00865.xDOI: 10.1111/j.1468-1293.2010.00865.x
Total and unbound lopinavir/ritonavir (LPV/r) concentrations in the genital tract (fGT) of HIV-1 infected women during pregnancy. (Conference Paper)
Lyons, F., Else, L., O'Shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2010). Total and unbound lopinavir/ritonavir (LPV/r) concentrations in the genital tract (fGT) of HIV-1 infected women during pregnancy.. In Second Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH) (pp. P9). Manchester: BHIVA.
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. (Journal article)
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. J. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.. Chromatogr B Analyt Technol Biomed Life Sci., 878(19), 1455-1465.
2009
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. (Journal article)
Pollock, L., Else, L., Poerksen, G., Molyneux, E., Moons, P., Walker, S., . . . Khoo, S. (2009). Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.. The Journal of antimicrobial chemotherapy, 64(6), 1251-1259. doi:10.1093/jac/dkp358DOI: 10.1093/jac/dkp358
Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients (Journal article)
Yilmaz, A., Watson, V., Else, L., & Gisslèn, M. (2009). Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS, 23(18), 2537-2540. doi:10.1097/qad.0b013e328333ae0eDOI: 10.1097/qad.0b013e328333ae0e
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. (Journal article)
Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.. The Journal of antimicrobial chemotherapy, 63(6), 1233-1243.
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers (Journal article)
Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 63(6), 1233-1243. doi:10.1093/jac/dkp102DOI: 10.1093/jac/dkp102
Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. (Journal article)
Yilmaz, A., Watson, V., Else, L., & Gissien, M. (2009). Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.. AIDS, 23(18), 2537-2540.
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. (Journal article)
Pollock, L., Else, L., Poerksen, G., Molyneux, E., Moons, P., Walker, S., . . . Khoo, S. (2009). Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.. J Antimicrob Chemother., 64(6), 1251-1259.
Else, L. (2009). The role of pharmacokinetics in optimising antiretroviral therapy in HIV-infected patients. (PhD Thesis, University of Liverpool).
2008
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. (Journal article)
Moltó, J., Santos, J. R., Pérez-Alvarez, N., Cedeño, S., Miranda, C., Khoo, S., . . . Clotet, B. (2008). Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.. Antimicrobial agents and chemotherapy, 52(11), 3928-3932. doi:10.1128/aac.00520-08DOI: 10.1128/aac.00520-08
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. (Journal article)
Moltó, J., Santos, J. R., Pérez-Alvarez, N., Cedeño, S., Miranda, C., Khoo, S., . . . Clotet, B. (2008). Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.. Antimicrobial agents and chemotherapy, 52(11), 3928-3932.
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation (Journal article)
Back, D., Else, L., Khoo, S., Boffito, M., Taylor, J., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. ANTIVIRAL THERAPY, 13(7), 901-907.
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. (Journal article)
Boffito, M., Else, L., Back, D., Taylor, J., Khoo, S., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.. Antiviral therapy, 13(7), 901-907.
Therapeutic Drug Monitoring of new formulation Kaletra in pregnancy (Conference Paper)
Else, L., Jackson, V., Khoo, S., Gibbons, S., Brennan, M., O Connor, E., . . . Lambert, J. S. (2008). Therapeutic Drug Monitoring of new formulation Kaletra in pregnancy. In The 9th International Congress on Drug Therapy in HIV Infection Vol. 11 (pp. P119). Glasgow: Journal of the International AIDS Society.
Total and unbound nevirapine (NVP) pharmacokinetics (PK) in HIV-infected children treated with divided fixed-dose combination (FDC) tablets in Malawi. (Conference Paper)
Else, L., Pollock, L., Poerkson, G., Back, D. J., Khoo, S. H., Fraser, W., . . . Molyneux, E. (2008). Total and unbound nevirapine (NVP) pharmacokinetics (PK) in HIV-infected children treated with divided fixed-dose combination (FDC) tablets in Malawi.. In 9th International Workshop on Clinical Pharmacology of HIV Therapy (pp. O7). New Orleans: Virology Education.
Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds. (Conference Paper)
Else, L., Watson, V., Tjia, J., Siccardi, M., Khoo, S. H., & Back, D. J. (2008). Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds.. In British Pharmacological Society Winter Meeting (pp. n/a). Brighton: British Pharmacological Society, 16 Angel Gate, City Road, London, UK.
2007
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. (Journal article)
Waters, L. J., Moyle, G., Bonora, S., D'Avolio, A., Else, L., Mandalia, S., . . . Boffito, M. (2007). Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.. Antiviral therapy, 12(5), 825-830.
